Related Experiment Video
Updated: Mar 21, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Anticoagulation in Pulmonary Arterial Hypertension.
Jeffrey C Robinson1, Steven C Pugliese1, Daniel L Fox1
1Colorado Pulmonary Vascular Disease Center, Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Anticoagulation shows potential for treating pulmonary arterial hypertension (PAH), a condition affecting blood flow in the lungs. However, more rigorous trials are needed to confirm its effectiveness and guide treatment decisions for PAH patients.
Area of Science:
- Cardiovascular Medicine
- Pulmonary Hypertension Research
- Hematology
Background:
- Pulmonary arterial hypertension (PAH) involves complex changes in lung circulation, leading to right heart failure.
- Current PAH treatments primarily use pulmonary vasodilators, often in combination therapy.
- PAH is linked to coagulation abnormalities, suggesting anticoagulation as a potential therapeutic avenue.
Purpose of the Study:
- To review the current evidence on anticoagulation as a treatment for idiopathic pulmonary arterial hypertension (PAH).
- To highlight the need for well-controlled prospective trials to clarify the role of anticoagulation in PAH management.
Main Methods:
- Review of observational studies on anticoagulation in idiopathic PAH.
- Analysis of existing literature regarding thrombosis and coagulation in PAH patients.
Main Results:
- Observational studies suggest a potential benefit of anticoagulation in idiopathic PAH.
- A significant lack of high-quality, prospective, controlled trials exists for anticoagulation in PAH.
- Conflicting evidence contributes to heterogeneity in current anticoagulation practices for PAH.
Conclusions:
- Anticoagulation is a frequently considered therapy for PAH due to associated thrombotic tendencies.
- The current evidence base is insufficient to establish definitive guidelines for anticoagulation in PAH.
- Further well-controlled prospective trials are essential to determine the precise role and efficacy of anticoagulation in treating pulmonary arterial hypertension.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

